Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Ion homeostasis is crucial for both normal and neoplastic cell survival.
• Cancer cells exhibit altered ion homeostasis, making ionophores potential therapeutic agents.
• Certain ionophores, including Salinomycin, Nigericin, and Obatoclax, show anticancer activity, particularly against chemoresistant cancer stem-like cells.

Purpose of the Study:

• To investigate the potential of ionophores as anticancer agents, focusing on their activity against cancer stem-like cells.
• To review the preclinical and clinical progress of ionophores in cancer therapy.
• To explore future directions for improving the efficacy of ionophore-based cancer treatments.

Main Methods:

• Review of preclinical studies (in vitro and in vivo) on ionophores like Salinomycin, Nigericin, and Obatoclax.
• Analysis of clinical trial data, specifically Phase I/II trials involving Obatoclax.
• Exploration of potential therapeutic strategies, including targeted drug delivery and derivative development.

Main Results:

• Preclinical studies demonstrated potent anticancer activities of specific ionophores against cancer stem-like cells.
• Clinical trials with Obatoclax, alone or in combination, showed limited benefits.
• Challenges exist in translating preclinical findings into effective clinical treatments.

Conclusions:

• Ionophores represent a promising class of compounds for targeting cancer stem-like cells due to their ability to disrupt altered ion homeostasis.
• Despite preclinical success, clinical efficacy of current ionophores is limited, highlighting the need for further research.
• Future strategies involving targeted drug delivery or the development of less toxic derivatives are essential for advancing ionophore-based cancer therapies.